Quest Diagnostics Achieves Strong Revenue Growth and EPS Increase in Q3 2026

Quest Diagnostics Financial Overview for Q3 2026

Quest Diagnostics Incorporated, traded under the NYSE ticker DGX, has released its financial results for the third quarter ending September 30, 2026. The report reveals a remarkable growth trajectory, with revenues rising to $3.10 billion, reflecting a 10.0% increase compared to the same period in 2025. This upward trend demonstrates the company's ability to capitalize on its diverse service channels, including physician, hospital, and consumer segments.

Significant Financial Highlights

Key figures from the third quarter of 2026 indicate steady growth in earnings as well. The reported diluted earnings per share (EPS) reached $2.78, marking a significant increase of 28.7% from the previous year. An adjusted diluted EPS of $3.00 shows a 15.4% rise, further affirming the company's solid performance amidst challenging market conditions.

For the entire year, Quest Diagnostics has updated its revenue projections, now expecting to generate between $12.065 billion and $12.105 billion. Furthermore, the guidance for reported diluted EPS has been adjusted upward, with estimates now ranging between $10.21 and $10.31 and adjusted diluted EPS between $11.25 and $11.35.

Leadership Insights

Jim Davis, Chairman, CEO, and President of Quest Diagnostics, attributed the revenue and EPS growth to the company’s strategic focus on automation and AI, enhancing productivity and meeting the clinical care demands of an aging population. He emphasized that the company’s solutions are increasingly catering to those prioritizing health prevention and wellness, driving the organic revenue growth.

Recent Developments and Innovations

Recent innovations have also contributed to Quest Diagnostics' growth. One notable development is the company’s collaboration with Apple, allowing iPhone and iPad users in the U.S. to purchase tailor-made laboratory test panels via the Apple Health app, enabling easier access to important health data for the public.

Moreover, Quest Diagnostics has inked a definitive agreement to acquire outreach lab assets from a prominent health system in the Northeastern U.S., which signifies its commitment to expanding lab services and solutions.

The company is also advancing its Co-Lab Solutions in partnership with Corewell Health in Michigan, moving forward with the design and implementation phases of Project Nova, aimed at deploying Epic solutions in their labs by fall 2027.

Outlook for Future Growth

The financial results hint at a positive outlook for Quest Diagnostics as it prepares for its 2027 Investor Day scheduled for March 25, 2027, at the New York Stock Exchange. This event is expected to showcase the company’s strategic initiatives aimed at growing its footprint and leveraging technical advancements in the healthcare domain.

Quest Diagnostics continues to be a leader in diagnostic information services, emphasizing its commitment to improving healthcare through insightful laboratory testing that caters to diverse health needs. With a workforce of nearly 60,000 employees, the company maintains a strong presence, serving a vast number of physicians and hospitals across the United States, and aims to enhance patient care by transforming diagnostic services.

Conclusion

In summary, Quest Diagnostics has reported impressive financial achievements for Q3 2026, positioning itself well for future growth. With increased revenue guidance and a focus on innovation and quality service delivery, the company is poised for continued success in the evolving healthcare landscape.